What’s Ahead for 2024?
As we dive into 2024, we asked our ADVI experts what they think the most compelling or anticipated healthcare issues will be this year. From a continued emphasis on the Inflation Reduction Act (IRA) to upcoming launches in cell and gene therapy, challenging payer dynamics, greater challenges for patient access, and cell and gene therapy access model updates, there is much to look forward to this year.
Peter Kardel, chief data scientist with the ADVI Strategic Analytics, Value and Economics team, discusses anticipated advancements in the health economic outcomes research (HEOR) space relating to new medications hitting the market and potential savings opportunities.
Learn More
Stay ahead of the curve this year. Get in touch today to gain expert insights and strategic counsel on the evolving healthcare landscape.
CEO insights
Related articles
Real analysis from people who’ve been there
Why Clinical Laboratories Should Consider Weighing In on CMS and CDC’s New CLIA Request for Information
An opportunity for laboratories to help shape the future of CLIA regulation On July 16, 2026, the Centers for Medicare …
RAND/UCLA Modified Delphi Panels
ADVI Health partners with pharmaceutical and biotech organizations to advance their evidence generation and market access strategies. We support complex research questions through primary research (e.g., …
Caitlin Sheetz, MPH
June 23, 2026
The MolDX Technical Assessment: How to Move Your Test from “Not Successful” to Medicare Coverage Success
In the laboratory space, the MolDX Technical Assessment (TA) is often the moment where the gap between “a great test” …
CRUSH and Genetic and Molecular Laboratories: A Potential Shift in Medicare Oversight
Genetic, molecular, and reference laboratories are closely watching a new Medicare concept known as CRUSH- short for Comprehensive Regulations to …
March Is Colorectal Cancer Awareness Month: Why CMS’s Proposed NCD 210.3 Update Could Accelerate Patient‑Centered Screening Access
Colorectal cancer (CRC) screening saves lives, but only when patients are able to access care in a way that meets …
The 2026 Rare Disease Reality
Orphan drugs now represent approximately 20 percent of total prescription spend, and over 52 percent of the cell and gene …
Marc Samuels, JD, MPH
February 26, 2026
A New Era for Cancer Detection Begins with the Sewell MCED Law
We are seeing a long‑anticipated and important policy inflection point. By now you might have heard that Congress passed the …
How HEOR and Real-World Evidence Are Reshaping Decisions in 2026
By 2026, health economics and outcomes research (HEOR) and real-world evidence (RWE) will look less like a supporting function and …
Reach out
Own your edge
We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.